Equities research analysts predict that Affimed NV (NASDAQ:AFMD) will report earnings per share of ($0.16) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Affimed’s earnings, with estimates ranging from ($0.19) to ($0.14). Affimed posted earnings per share of ($0.18) during the same quarter last year, which would suggest a positive year over year growth rate of 11.1%. The business is scheduled to announce its next quarterly earnings report on Tuesday, May 21st.
On average, analysts expect that Affimed will report full year earnings of ($0.48) per share for the current financial year, with EPS estimates ranging from ($0.70) to ($0.05). For the next year, analysts forecast that the business will post earnings of ($0.29) per share, with EPS estimates ranging from ($0.72) to $0.81. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Affimed.
Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. The company had revenue of $25.96 million during the quarter. Affimed had a negative net margin of 87.00% and a negative return on equity of 44.56%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AFMD. D. E. Shaw & Co. Inc. bought a new stake in shares of Affimed in the 4th quarter worth approximately $36,000. Lindbrook Capital LLC bought a new stake in shares of Affimed in the 4th quarter worth approximately $38,000. Bourgeon Capital Management LLC bought a new stake in shares of Affimed in the 1st quarter worth approximately $42,000. Sigma Planning Corp bought a new stake in shares of Affimed in the 1st quarter worth approximately $46,000. Finally, FDx Advisors Inc. bought a new stake in shares of Affimed in the 4th quarter worth approximately $87,000. Institutional investors and hedge funds own 41.08% of the company’s stock.
Shares of NASDAQ:AFMD opened at $3.42 on Tuesday. The company has a market capitalization of $217.12 million, a PE ratio of -9.00 and a beta of 3.23. Affimed has a twelve month low of $1.40 and a twelve month high of $7.35. The company has a quick ratio of 3.00, a current ratio of 3.01 and a debt-to-equity ratio of 0.04.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.